vs
Side-by-side financial comparison of Ovid Therapeutics Inc. (OVID) and TaoWeave, Inc. (TWAV). Click either name above to swap in a different company.
Ovid Therapeutics Inc. is the larger business by last-quarter revenue ($718.0K vs $622.0K, roughly 1.2× TaoWeave, Inc.). On growth, Ovid Therapeutics Inc. posted the faster year-over-year revenue change (844.7% vs 10.5%). Over the past eight quarters, Ovid Therapeutics Inc.'s revenue compounded faster (120.3% CAGR vs -0.3%).
OVID vs TWAV — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $718.0K | $622.0K |
| Net Profit | — | $-2.8M |
| Gross Margin | — | 47.1% |
| Operating Margin | — | -126.4% |
| Net Margin | — | -448.2% |
| Revenue YoY | 844.7% | 10.5% |
| Net Profit YoY | 204.4% | -215.4% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $718.0K | $622.0K | ||
| Q3 25 | $132.0K | $601.0K | ||
| Q2 25 | $6.3M | $592.0K | ||
| Q1 25 | $130.0K | $622.0K | ||
| Q4 24 | $76.0K | $563.0K | ||
| Q3 24 | $173.0K | $578.0K | ||
| Q2 24 | $169.0K | $611.0K | ||
| Q1 24 | $148.0K | $626.0K |
| Q4 25 | — | $-2.8M | ||
| Q3 25 | $-12.2M | $-2.3M | ||
| Q2 25 | $-4.7M | $-605.0K | ||
| Q1 25 | $-10.2M | $-672.0K | ||
| Q4 24 | — | $-884.0K | ||
| Q3 24 | $-14.0M | $-1.0M | ||
| Q2 24 | $8.5M | $-983.0K | ||
| Q1 24 | $-11.7M | $-1.1M |
| Q4 25 | — | 47.1% | ||
| Q3 25 | — | 40.6% | ||
| Q2 25 | — | 38.5% | ||
| Q1 25 | — | 40.0% | ||
| Q4 24 | — | 24.0% | ||
| Q3 24 | — | 13.7% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | -0.5% |
| Q4 25 | — | -126.4% | ||
| Q3 25 | -9487.1% | -133.4% | ||
| Q2 25 | -80.9% | -115.4% | ||
| Q1 25 | -9653.8% | -111.1% | ||
| Q4 24 | — | -164.8% | ||
| Q3 24 | -7645.1% | -185.5% | ||
| Q2 24 | -12140.2% | -166.6% | ||
| Q1 24 | -11768.2% | -189.1% |
| Q4 25 | — | -448.2% | ||
| Q3 25 | -9210.6% | -381.0% | ||
| Q2 25 | -74.7% | -102.2% | ||
| Q1 25 | -7873.1% | -108.0% | ||
| Q4 24 | — | -157.0% | ||
| Q3 24 | -8096.0% | -179.9% | ||
| Q2 24 | 5042.0% | -160.9% | ||
| Q1 24 | -7901.4% | -181.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.20 | — | ||
| Q2 24 | $0.12 | — | ||
| Q1 24 | $-0.17 | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.2M | $2.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $130.7M | $7.0M |
| Total Assets | $150.9M | $8.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.2M | $2.3M | ||
| Q3 25 | $20.6M | $3.7M | ||
| Q2 25 | $28.4M | $10.8M | ||
| Q1 25 | $21.1M | $4.3M | ||
| Q4 24 | $26.3M | $5.0M | ||
| Q3 24 | $15.0M | $5.6M | ||
| Q2 24 | $29.7M | $5.9M | ||
| Q1 24 | $30.8M | — |
| Q4 25 | $130.7M | $7.0M | ||
| Q3 25 | $44.7M | $9.8M | ||
| Q2 25 | $55.8M | $11.3M | ||
| Q1 25 | $59.3M | $3.4M | ||
| Q4 24 | $68.2M | $4.0M | ||
| Q3 24 | $76.3M | $4.7M | ||
| Q2 24 | $88.9M | $5.1M | ||
| Q1 24 | $78.3M | $4.4M |
| Q4 25 | $150.9M | $8.2M | ||
| Q3 25 | $63.8M | $10.9M | ||
| Q2 25 | $77.4M | $13.1M | ||
| Q1 25 | $81.7M | $4.8M | ||
| Q4 24 | $92.2M | $5.3M | ||
| Q3 24 | $102.7M | $6.0M | ||
| Q2 24 | $118.1M | $6.3M | ||
| Q1 24 | $131.6M | $5.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-38.3M | $-744.0K |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-38.3M | $-744.0K | ||
| Q3 25 | $-12.9M | $-1.6M | ||
| Q2 25 | $-4.8M | $-37.0K | ||
| Q1 25 | $-10.3M | $-680.0K | ||
| Q4 24 | $-56.0M | $-255.0K | ||
| Q3 24 | $-15.0M | $-911.0K | ||
| Q2 24 | $-14.3M | $-1.6M | ||
| Q1 24 | $-16.7M | $-630.0K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-56.0M | — | ||
| Q3 24 | $-15.0M | — | ||
| Q2 24 | $-14.3M | — | ||
| Q1 24 | $-16.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -73719.7% | — | ||
| Q3 24 | -8676.9% | — | ||
| Q2 24 | -8455.0% | — | ||
| Q1 24 | -11287.2% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 93.4% | — | ||
| Q3 24 | 2.3% | — | ||
| Q2 24 | 20.1% | — | ||
| Q1 24 | 12.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.67× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
